Leqembi Phase II Missed Clinical Endpoint But Still Provided Support For Amyloid Surrogate

 
• By Sue Sutter
  
Drug Review Profile: Leqembi
The primary clinical efficay endpoint's failure to hit its prespecified mark was no hurdle to accelerated approval. • Source: Pink Sheet/Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Drug Review Profiles

More from Product Reviews